Clinical Trials in North Carolina

Showing 10181-10200 of 15,496 trials

A Study of Ixekizumab in Participants With Plaque Psoriasis

NCT02993471

This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome P450. Each participant will complete two study periods. Participants will take the mixture of commonly used drugs (plus vitamin K) by mouth on 3 occasions (prior to treatment with ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). The study will last about 17 weeks, including follow-up. Screening must be completed prior to study start.

Psoriasis

Eli Lilly and Company28 participantsStarted Dec 2016

Anaheim, California, United States • DeLand, Florida, United States • High Point, North Carolina, United States

TERMINATEDPhase 338 miles

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

NCT01785771

An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day

Type 2 Diabetes

Intarcia Therapeutics100 participantsStarted May 2013

Birmingham, Alabama, United States • Gulf Shores, Alabama, United States • Chandler, Arizona, United States +48 more locations

A Study of Ixekizumab in Participants With Plaque Psoriasis

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Find Trials by Condition in North Carolina

Pain Expectations in Subjects With Osteoarthritis

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

Driveline Silicone Skin Interface Registry

Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors

The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Validation of Non-Invasive Intracranial Pressure (ICP) Monitoring Device

Dating Matters: Strategies to Promote Healthy Teen Relationships

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Inflammation and the Host Response to Injury (Trauma)

Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)

Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation